Education
About Us
Working with TipRanks
Follow Us
Enlivex Therapeutics (ENLV)
:ENLV
ENLV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.81 - $1.76
Previous CloseN/A
Volume59.48K
Average Volume (3M)110.08K
Market Cap
$27.90M
Enterprise Value$27.79M
Total Cash (Recent Filing)$20.55M
Total Debt (Recent Filing)$503.00K
Price to Earnings (P/E)―
Beta1.29
Next Earnings
May 23, 2025EPS Estimate
-0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding23,849,936
10 Day Avg. Volume123,029
30 Day Avg. Volume110,085
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-2.22
Enterprise Value/Market Cap1.00
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-62.16
Enterprise Value/Ebitda-0.45
Forecast
1Y Price Target
$7.00Price Target Upside498.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Enlivex News
PremiumCompany Announcements
Enlivex Reports Q1 2025 Financial Results with Reduced Loss
PremiumCompany Announcements
Enlivex to Present Allocetra™ Insights at OARSI 2025
PremiumCompany Announcements
Enlivex Completes Phase II Enrollment for Osteoarthritis TrialBulls Say, Bears Say
Bulls Say
Efficacy DataEnlivex has reported positive interim efficacy data for patients in Phase 1 with significant improvements and no safety issues.
Intellectual PropertyChinese patent claims allowed for Allocetra in osteoarthritis treatment, providing added protection through at least 2040.
Bears Say
Clinical TrialThe Phase 2 trial will rigorously evaluate joint-pain and function with a double-blind, randomized, placebo-controlled design.
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.04% Mutual Funds
<0.01% Other Institutional Investors
99.34% Public Companies and
Individual Investors
ENLV FAQ
What was Enlivex Therapeutics’s price range in the past 12 months?
Enlivex Therapeutics lowest stock price was $0.81 and its highest was $1.76 in the past 12 months.
What is Enlivex Therapeutics’s market cap?
Enlivex Therapeutics’s market cap is $27.90M.
When is Enlivex Therapeutics’s upcoming earnings report date?
Enlivex Therapeutics’s upcoming earnings report date is May 23, 2025 which is 64 days ago.
How were Enlivex Therapeutics’s earnings last quarter?
Enlivex Therapeutics released its earnings results on May 24, 2024. The company reported -$0.25 earnings per share for the quarter, the consensus estimate of -$0.25 by $0.
Is Enlivex Therapeutics overvalued?
According to Wall Street analysts Enlivex Therapeutics’s price is currently Undervalued.
Does Enlivex Therapeutics pay dividends?
Enlivex Therapeutics does not currently pay dividends.
What is Enlivex Therapeutics’s EPS estimate?
Enlivex Therapeutics’s EPS estimate is -0.15.
How many shares outstanding does Enlivex Therapeutics have?
Enlivex Therapeutics has 23,849,936 shares outstanding.
What happened to Enlivex Therapeutics’s price movement after its last earnings report?
Enlivex Therapeutics reported an EPS of -$0.25 in its last earnings report, expectations of -$0.25. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Enlivex Therapeutics?
Currently, no hedge funds are holding shares in ENLV
Enlivex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (498.29% Upside)
$7.00 (498.29% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.1%
Last 30 Days ▼ 8.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-18.75%
12-Months-Change
Fundamentals
Return on Equity
-60.35%
Trailing 12-Months
Asset Growth
-22.59%
Trailing 12-Months
Company Description
Enlivex Therapeutics
Enlivex (NASDAQ: ENLV) is a clinical-stage biopharmaceutical company engaged in the development of innovative immunotherapy treatments. The company is primarily focused on discovering and developing cell therapies designed to treat life-threatening conditions resulting from the overreaction of the immune system, such as sepsis and cancer. Enlivex's core product candidate is Allocetra, a cell therapy intended to modulate immune system responses and restore balance to the immune system.